Listen

Add to my selection

LIBTAYO

Medicine - Posted on Jan 12 2024

Active substance (DCI)

cemiplimab

history (7)

1/10/24

LIBTAYO (cemiplimab) - Non Small Cell Lung Cancer (NSCLC)

-

CAV :
54321

icône flèche
8/30/23

LIBTAYO (cémiplimab) - Carcinome épidermoïde cutané métastatique ou localement avancé (CECm ou CECla)

Réévaluation à la demande du laboratoire. L'essentiel Avis favorable au remboursement dans le sous-groupe de patients attein...

CAV :
54321

icône flèche
4/5/23

LIBTAYO (cemiplimab) - Cervical cancer

New indication(s). Key points Favourable opinion on reimbursement solely in patients with recurrent or metastatic cervical c...

CAV :
54321

icône flèche
9/14/22

LIBTAYO (cémiplimab) - CBCla ou CBCm

Key points Approval of the reimbursement of LIBTAYO (cemiplimab) monotherapy for the treatment of adult patients with locall...

CAV :
54321

icône flèche
11/17/21

LIBTAYO 350 mg (cémiplimab)

Key points Favourable opinion for reimbursement in the subgroup of patients with metastatic or locally advanced cutaneous sq...

CAV :
54321

icône flèche
10/6/21

LIBTAYO 350 mg (cémiplimab) (CBNPC)

Key points Favourable opinion for reimbursement as monotherapy for the first-line treatment of adult patients with non-small...

CAV :
54321

icône flèche

3/18/20

LIBTAYO (cemiplimab)

Key points Favourable opinion for reimbursement in the treatment of adult patients with metastatic or locally advanced cutan...

CAV :
54321

icône flèche

Technical information

ATC code

L01FF06

Manufacturer

SANOFI-AVENTIS FRANCE

Presentation

LIBTAYO 350 mg, solution à diluer pour perfusion
1 flacon en verre de 7 ml (CIP : 34009 550 672 8 3)

All our publications

Genital cancers

Respiratory tract cancers

Skin and connective tissue cancers